These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 32885994

  • 1. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
    Dror CM, Chi KN.
    Future Oncol; 2020 Dec; 16(35):2905-2916. PubMed ID: 32885994
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ.
    Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
    [Abstract] [Full Text] [Related]

  • 4. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Juárez Soto Á, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN, TITAN investigators.
    Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.
    Hoy SM.
    Drugs; 2020 Oct; 80(15):1579-1585. PubMed ID: 32930958
    [Abstract] [Full Text] [Related]

  • 7. Apalutamide and its use in the treatment of prostate cancer.
    Borno HT, Small EJ.
    Future Oncol; 2019 Feb; 15(6):591-599. PubMed ID: 30426794
    [Abstract] [Full Text] [Related]

  • 8. Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide.
    Lowentritt BH, Du S, Rossi C, Muser E, Khilfeh I, Kinkead F, Korsiak J, Lefebvre P, Pilon D, Agarwal N.
    Future Oncol; 2024 Feb; 20(27):2005-2013. PubMed ID: 38861305
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S, TITAN Investigators.
    N Engl J Med; 2019 Jul 04; 381(1):13-24. PubMed ID: 31150574
    [Abstract] [Full Text] [Related]

  • 11. Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide.
    Bivins VM, Durkin M, Khilfeh I, Rossi C, Kinkead F, Waters D, Lefebvre P, Pilon D, Ellis L.
    Future Oncol; 2022 Oct 04; 18(32):3595-3607. PubMed ID: 36196743
    [Abstract] [Full Text] [Related]

  • 12. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J, Zhang L, Amatya A, Gong Y, King-Kallimanis B, Bhatnagar V, Weinstock C, Suzman DL, Agrawal S, Chang E, Anscher MS, Chi DC, Xu JX, Brewer JR, Brave MH, Hadadi M, Theoret MR, Kluetz PG, Goldberg KB, Ibrahim A, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L, Singh H.
    Lancet Oncol; 2021 Sep 04; 22(9):1230-1239. PubMed ID: 34310904
    [Abstract] [Full Text] [Related]

  • 13. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
    Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, Smaletz O, Schutz F, Herchenhorn D, Santos T, Mavignier Carcano F, Queiroz Muniz D, Nunes Filho PRS, Zaffaroni F, Barrios C, Fay A.
    BMC Cancer; 2019 May 23; 19(1):487. PubMed ID: 31122212
    [Abstract] [Full Text] [Related]

  • 14. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
    Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE.
    Eur Urol; 2016 Dec 23; 70(6):963-970. PubMed ID: 27160947
    [Abstract] [Full Text] [Related]

  • 15. An evaluation of apalutamide for the treatment of prostate cancer.
    Boukovala M, Spetsieris N, Efstathiou E.
    Expert Opin Pharmacother; 2020 Sep 23; 21(13):1537-1546. PubMed ID: 32543237
    [Abstract] [Full Text] [Related]

  • 16. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
    Tsuchiya T, Imanaka K, Iwaki Y, Oyama R, Hashine K, Yamaguchi A, Uemura H.
    Int J Clin Oncol; 2019 Dec 23; 24(12):1596-1604. PubMed ID: 31446511
    [Abstract] [Full Text] [Related]

  • 17. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 23; 37(1):512-526. PubMed ID: 31813087
    [Abstract] [Full Text] [Related]

  • 18. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.
    Adv Ther; 2020 Jan 23; 37(1):501-511. PubMed ID: 31813086
    [Abstract] [Full Text] [Related]

  • 19. Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
    Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Soto ÁJ, Uemura H, Ye DW, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN.
    Future Oncol; 2024 Mar 23; 20(10):563-578. PubMed ID: 38126311
    [Abstract] [Full Text] [Related]

  • 20. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
    Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ, SPARTAN Investigators.
    N Engl J Med; 2018 Apr 12; 378(15):1408-1418. PubMed ID: 29420164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.